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Background. Weakness is common and contributes to disability, but no consensus exists regarding a strength cutpoint 
to identify persons at high risk. This analysis, conducted as part of the Foundation for the National Institutes of Health 
Sarcopenia Project, sought to identify cutpoints that distinguish weakness associated with mobility impairment, defined 
as gait speed less than 0.8 m/s.
Methods. In pooled cross-sectional data (9,897 men and 10,950 women), Classification and Regression Tree analysis 
was used to derive cutpoints for grip strength associated with mobility impairment.
Results. In men, a grip strength of 26–32 kg was classified as “intermediate” and less than 26 kg as “weak”; 11% of 
men were intermediate and 5% were weak. Compared with men with normal strength, odds ratios for mobility impair-
ment were 3.63 (95% CI: 3.01–4.38) and 7.62 (95% CI 6.13–9.49), respectively. In women, a grip strength of 16–20 kg 
was classified as “intermediate” and less than 16 kg as “weak”; 25% of women were intermediate and 18% were weak. 
Compared with women with normal strength, odds ratios for mobility impairment were 2.44 (95% CI 2.20–2.71) and 
4.42 (95% CI 3.94–4.97), respectively. Weakness based on these cutpoints was associated with mobility impairment 
across subgroups based on age, body mass index, height, and disease status. Notably, in women, grip strength divided by 
body mass index provided better fit relative to grip strength alone, but fit was not sufficiently improved to merit different 
measures by gender and use of a more complex measure.
Conclusions. Cutpoints for weakness derived from this large, diverse sample of older adults may be useful to identify 
populations who may benefit from interventions to improve muscle strength and function.
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MUSCLE weakness is related to poor physical per-formance and incident mobility limitations among 
older adults (1–6). Weakness is considered a key element of 
frailty (7) and, increasingly, of sarcopenia (8,9). Although 
the association between weakness and functional limitations 
is strong, there is no consensus regarding a cutpoint for iden-
tification of risk for functional problems. In order to identify 
population subgroups in whom weakness is a potential con-
tributor to functional limitations, it is necessary to determine 
what constitutes a clinically relevant degree of weakness.
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This is the second in a series of reports from the 
Foundation for the National Institutes of Health (FNIH) 
Sarcopenia Project, which pooled data from multiple stud-
ies to develop and evaluate clinically relevant criteria for 
weakness and low muscle mass (10). The purpose of the 
analysis presented here was to identify cutpoints that dis-
tinguish weakness (measured by grip strength) associated 
with mobility impairment (measured by gait speed) using 
cross-sectional data (ie, to maximize concurrent validity). 
This analysis builds on previous research on the association 
between strength and walking speed using a data-driven 
approach across multiple populations and an analytic tech-
nique (Classification and Regression Tree [CART] analy-
sis) designed to optimize concurrent validity in the context 
of complex interactions. Findings were used to address sub-
sequent Project goals reported separately (11–13).
Methods
Participants
Data available for this phase of the FNIH Sarcopenia 
Project analysis included: the Study of Osteoporotic 
Fractures, both the original cohort (study Visit 6) (14) 
and African American cohort (study Visit 1) (15); the 
Osteoporotic Fractures in Men Study (baseline visit) (16); 
the Health, Aging and Body Composition Study (Year 
6 Clinic Visit) (17); the Framingham Study (both the 
Offspring cohort [exam cycles 6 and 7, 1996–2001] (18) 
and Original cohort [exam cycle 26, 1999–2001]) (19); the 
InCHIANTI Study (Aging in the Chianti Area, Year 3 visit) 
(20); the Boston Puerto Rican Health Study (baseline visit) 
(21); the Age, Gene/Environment Susceptibility-Reykjavik 
Study (baseline visit) (22); and four clinical trials from the 
University of Connecticut (UCONN, randomization visit 
for all studies) (23–26).
To be included in these analyses, participants were 
required to have height and weight, grip strength, and gait 
speed measured at a single time point: Of the 26,625 par-
ticipants aged 65 and older in the pooled data, 1,403 were 
ineligible because they were in studies that did not collect 
the variables used in this analysis; 1,978 were not eligible 
for assessment of key measures within their study; and an 
additional 2,397 were excluded due to missing data, yield-
ing a final sample size of 20,847 (9,897 men and 10,950 
women). Participants excluded due to missing data were 
older, slower, weaker, had lower body mass index (BMI), 
higher rates of chronic conditions, and were more likely to 
be women.
Measures
Walking speed less than 0.8 m/s was selected as the pri-
mary outcome for the FNIH Sarcopenia Project because 
of its strong longitudinal associations with disability and 
mortality and because its use has been recommended by 
other experts (refs. (9) and (10)). Detailed descriptions of 
gait speed assessment are available elsewhere (10).
Grip strength was selected as the primary measure of 
strength for several reasons. It is clearly related to mobility 
outcomes (4,6,27) and is easy to use in both clinical and 
community settings. Standard protocols are available for 
use without a high level of investigator training, and simi-
lar protocols were used across Project studies. Conversely, 
measures of lower extremity strength were inconsistent 
across participating studies. Preliminary analysis suggested 
that grip strength explained a similar amount of variance 
in walking speed compared with knee extension strength 
(R2 for grip strength  =  .01–.16, R2 for knee extension 
strength = .04–.17).
Grip strength was measured by handheld dynamom-
eter (28). A  summary of study protocols is available in 
Supplementary Appendix Table 1). The majority of studies 
(11 out of 13 cohorts) utilized Jamar dynamometers. The 
maximum strength value in either hand was analyzed.
Statistical Analysis
Our approach relied on identifying a level of grip strength 
below which older persons are more likely to have a mobil-
ity impairment (gait speed < 0.8 m/s). Individual-level data 
from all cohorts were combined into a single, pooled data 
set. Scatterplots with overlaid locally weighted scatterplot 
smoothing (LOESS) curves were used to describe the shape 
of the relationship between grip strength and gait speed.
CART analysis was then performed as the primary 
method for deriving cutpoints for muscle strength (29). 
Briefly, CART recursively partitions study participants into 
mutually exclusive groups defined by predictor cutpoints 
within which participants have similar outcome probabili-
ties. CART is virtually free of modeling assumptions, which 
provides several advantages in this context: (i) it optimizes 
concurrent validity by identifying predictors and cutpoints 
with the strongest relationship with the outcome based on 
the criterion of minimum error sum of squares; (ii) it does 
not require an a priori specified number of cutpoints; and 
(iii) it can identify complex interactions (ie, nonlinear inter-
actions involving multiple variables) with other potentially 
important variables (eg, BMI, height). CART has been used 
previously to study the association between strength and 
walking speed (5,30).
CART analysis was performed using R version 2.10.1, 
and cross-validation was used to select the best-perform-
ing cutpoints. Internal cross-validation is intended to avoid 
overfitting and development of sample-specific cutpoints. 
Cross-validation was performed by randomly partitioning 
the pooled data into 10 equally sized mutually exclusive 
subsamples (ie, each sample excluded 10% of the original 
pooled data). The tree was then applied to the 10 subsamples 
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each of which contained 90% of the data, and the error vari-
ance (called the prediction error, calculated using the error 
sum of squares) from each subsample was calculated. The 
10 prediction errors were used to calculate the empirical 
standard error of the prediction error. Following published 
guidelines (31), the tree was pruned to the most parsimoni-
ous tree within one standard error of the tree with the small-
est prediction error. This pruned tree contains the final set of 
strength cutpoints from pooled analysis.
Several sets of candidate predictors were included in 
CART models to identify the most appropriate model for 
the prediction of slow gait speed: maximum grip strength, 
body size indicators (BMI, height, weight), and the ratio 
of strength to body size (grip strength/height, grip strength/
weight, grip strength/height2, and grip strength/BMI), 
because previous research suggests that the association 
between strength and mobility may differ across strata of 
BMI (4).
Sensitivity analysis examined the predictive power of 
recommended cutpoints across cohorts and by characteris-
tics such as age, BMI, height, and comorbidities. Cutpoints 
were evaluated by predicting slow walking speed based 
on strength category in a mixed-effects logistic regression 
model including indicator functions for cutpoints as fixed 
effects and random intercepts accounting for heterogeneity 
between data sets. Additional sensitivity analysis examined 
the stability of CART-derived cutpoints using alternative 
gait speed outcomes (<0.6 m/s and continuous gait speed). 
Although additional analyses were planned based on inabil-
ity to rise from a chair (an alternative physical performance 
measure), only 3.8% of men and 6.0% of women met this 
criterion, providing insufficient sample size to implement 
those analyses.
Results
Sample descriptive characteristics are available in the 
online Supplementary Appendix and generally resemble 
characteristics of the parent studies described elsewhere 
(10). Figure 1 provides plots of the association between grip 
strength and gait speed in men and women. Visual inspec-
tion of the LOESS curves provided little evidence of a clear 
threshold effect of strength on continuous gait speed.
CART analysis predicting probability of slow walking 
(<0.8 m/s) yielded somewhat different results for men and 
women. In men, grip strength alone was the strongest pre-
dictor of slow walking (ie, resulted in the lowest relative 
error compared to other predictors), and CART analysis did 
not identify differences in grip strength cutpoints by BMI. 
In women, grip strength/BMI was the strongest predictor 
of slow walking. In order to further explore these gender 
effects, we evaluated cutpoints based on grip strength alone 
and grip strength/BMI in both men and women. We con-
ducted logistic regression using alternative definitions of 
weakness and comparing both model fit statistics and the 
strength of the associations between weakness and slow-
ness. Because the additional value of including BMI in 
the definition of weakness was unclear (ie, including BMI 
did not consistently improve model fit or result in stronger 
associations between weakness and slowness), we elected 
to use cutpoints based on grip strength alone as our primary 
analysis.
Figure 2 provides results for the primary definition. The 
first cutpoint identified in men was based on having grip 
strength equal to or above 31.83 kg versus below 31.83 kg. 
Within the low-strength group (<31.83 kg), a second cut-
point was identified at 25.99 kg. Among the weakest men 
(grip strength < 25.99 kg), 40.4% had slow gait speed, com-
pared with 20.6% among men with intermediate strength 
(grip strength of 25.99–31.82), and 5.7% among men in the 
highest strength group (grip strength ≥ 31.83).
The first cutpoint identified in women was based on hav-
ing grip strength equal to or above 19.99 kg versus below 
19.99 kg. Within the low-strength group (<19.99 kg), a sec-
ond cutpoint was identified at 15.92 kg. Among the weakest 
women (grip strength < 15.92 kg), 51.4% of women had 
slow gait speed, compared with 35.6% among women with 
intermediate strength (grip strength of 15.92–19.98 kg), and 
20.1% among women in the highest strength group (grip 
strength ≥ 19.99 kg).
Based on these results, we defined three strength catego-
ries for both men and women (normal strength, intermedi-
ate, and weak). Table 1 provides the prevalence of strength 
categories in the full sample, accounting for heterogene-
ity across studies, and provides the relative odds of slow 
walking across strength groups. The majority of men were 
classified as normal strength (84%), 11% were classified 
as intermediate, and 5% as weak. Men in the intermediate 
and weak groups, respectively, had 3.6 (odds ratio [OR] = 
3.63, 95% CI: 3.01–4.38) and 7.6 (OR = 7.62, 95% CI: 
6.13–9.49) times greater odds of having slow gait speed 
relative to men in the normal strength group. Over half 
of women were classified as normal strength (57%), 25% 
were classified as intermediate and 18% as weak. Women 
in the intermediate and weak groups, respectively, had 2.4 
(OR = 2.44, 95% CI: 2.20–2.71) and 4.4 (OR = 4.42, 95% 
CI: 3.94–4.97) times the odds of slow walking relative to 
women in the normal strength group. Test statistics (sensi-
tivity, specificity, positive predictive value) are provided in 
the Supplementary Appendix.
Table  1 also provides the results of sensitivity analysis 
across stratification variables. As expected, the prevalence of 
weakness varied across age, BMI, height, and diseases sta-
tus. However, in most cases, the excess prevalence of slow-
ness associated with weakness was similar across groups. 
For example, the prevalence of weakness was higher among 
women aged 80 and older (27%) than among women aged 
65–74 (12%). However, in both age groups, weakness was 
associated with an excess 3.5–3.7 times the odds of slow walk-
ing relative to normal strength. Notably, this was also true for 
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BMI. Underweight women were the most likely to be weak 
(32%), whereas obese women were the least likely to be weak 
(14%). However, weakness was associated with an excess 
4.4–4.8 times the odds of slow walking across all BMI groups.
Figure 1. Association of grip strength and gait speed in the FNIH Sarcopenia Project: scatterplot and smoothed locally weighted moving averages.
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Figure 1. Association of grip strength and gait speed in the FNIH Sarcopenia Project: scatterplot and smoothed locally weighted moving averages.
The only statistically significant interactions occurred in 
men, for age and height. The association between weakness 
and slow walking was stronger in men in the 65–79 age 
group (OR = 7.42, 95% CI: 5.28–10.43) than in men aged 
80 and older (OR = 4.17, 95% CI: 3.10–5.61). The asso-
ciation between weakness and slow walking was strongest 
in men in the tallest height tertile (OR = 10.24, 95% CI: 
5.98–17.54) compared with the lowest tertile (OR = 6.69, 
95% CI: 4.93–9.09).
Additional analysis (Supplementary Appendix Table  4) 
examined the prevalence of strength categories and low 
mobility across cohorts. Although the prevalence of weak-
ness and mobility limitations differed across cohorts, the 
relationship between weakness and mobility limitation was 
generally similar. Relationships were less consistent in the 
clinical trials and in the Boston Puerto Rican Health Study.
Sensitivity analysis also considered the stability of grip 
strength cutpoints based on alternative gait speed out-
comes (results not shown). In men, use of gait speed less 
than 0.6 m/s produced results similar to the main analysis 
(<26 kg), identifying a weak group with grip strength less 
than 25.90 kg. Use of a continuous gait speed outcome 
resulted in selection of a slightly higher cutpoint for weak-
ness (<27.94 kg). In women, both alternative specifications 
yielded slightly higher cutpoints for grip strength than the 
cutpoint found in the main analysis (<16 kg). Models using 
gait speed less than 0.6 m/s as the outcome identified a 
weak group with grip strength less than 17.78 kg, and mod-
els using a continuous gait speed outcome identified a weak 
group with grip strength less than 19.99 kg, similar to the 
“intermediate” group in the main analysis.
Results for an alternative definition utilizing grip 
strength/BMI are reported in the Supplementary Appendix 
and briefly summarized here. Using a definition of weak-
ness based on grip strength alone, 14% of obese women 
were classified as weak, and weakness in obese women was 
associated with 4.4 times the odds of slow walking rela-
tive to normal strength (OR = 4.41, 95% CI: 3.45–5.64). 
Alternatively, using a definition based on grip strength 
divided by BMI (see Supplementary Appendix Table  5), 
33% of obese women were classified as weak, and weak-
ness using this definition was associated with 4.8 times the 
odds of slow walking relative to normal strength (OR = 
4.84, 95% CI: 3.94–5.95). In contrast, underweight women 
were more likely to be classified as weak when using a defi-
nition based on grip strength alone (32%) than when using 
a definition based on grip strength divided by BMI (5%).
Discussion
The purpose of this analysis was to identify cutpoints that 
distinguish weakness associated with poor mobility perfor-
mance using cross-sectional data. The cutpoints developed 
here and carried forward in additional analysis as part of the 
FNIH Sarcopenia Project define grip strength less than 26 
kg in men and less than 16 kg in women as “weak.” These 
cutpoints classified 5% of men and 18% of women as weak, 
and weakness based on this definition was associated with 
more than 7 times the odds of slow walking in men and 
more than 4 times the odds of slow walking in women rela-
tive to normal strength. Cutpoints performed well across a 
range of subgroups defined by anthropometric characteris-
tics (BMI, height) and the presence of chronic conditions. 
In addition to identifying a weak group, models identified 
a group with detectable, although less severe weakness in 
both men and women (termed “intermediate”). This inter-
mediate level of weakness (<32 kg in men and <20 kg in 
women) was associated with 3.6 times the odds of slow 
walking in men and 2.4 times the odds of slow walking in 
women relative to normal strength.
Figure 2. Classification tree for gait speed <0.8 m/s in the FNIH Sarcopenia Project.
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The analytic approach used here focused on maximizing 
concurrent validity between strength and mobility impair-
ment. This approach resulted in a relatively conservative 
definition of weakness, based both on test statistics and on 
comparison to existing definitions. Our aim was to maxi-
mize confidence that the criterion was detecting a clinically 
relevant degree of weakness. In men who were not slow (ie, 
walking speed ≥ 0.8 m/s), only 3% were weak, whereas 23% 
of men who were slow were weak. In women who are not 
slow, 13% were weak, compared with 31% of women who 
are slow. Thus, the definition of weakness proposed here 
identifies a subgroup of older persons with a higher prob-
ability of combined weakness and slowness than expected 
in the older population.
Table 1. Sensitivity Analysis: Prevalence of Categories of Strength and Likelihood of Slowness Across Subsamples  
in the FNIH Sarcopenia Project
N
Prevalence of Strength Category, 
N (%)






p for  
Interaction†
Men ≥32.0 kg 26–31.9 kg <26 kg <26 kg 26–31.9 kg ≥32.0 kg
 All 9,897 8,312 (84.0) 1,065 (10.8) 520 (5.3) 1.0 (referent) 3.63 (3.01, 4.38) 7.62 (6.13,9.49)
 Age
  65–79 7,599 6,801 (89.5) 566 (7.5) 232 (3.1) 1.0 (referent) 4.45 (3.40, 5.82) 7.42 (5.28,10.43) <.001
  80 2,298 1,511 (65.8) 499 (21.7) 288 (12.5) 1.0 (referent) 1.74 (1.34, 2.27) 4.17 (3.10,5.61)
 Body mass index z
  Underweight 40 26 (65.0) 8 (20.0) 6 (15.0) 1.0 (referent) 3.30 (0.55, 19.65) 2.75 (0.37,20.40) .275
  Normal weight 2,814 2,257 (80.2) 360 (12.8) 197 (7.0) 1.0 (referent) 4.04 (2.89, 5.65) 10.17 (7.05,14.66)
  Overweight 5,000 4,260 (85.2) 507 (10.1) 233 (4.7) 1.0 (referent) 3.55 (2.67, 4.73) 8.10 (5.80,11.31)
  Obese 2,043 1,769 (86.6) 190 (9.3) 84 (4.1) 1.0 (referent) 3.60 (2.43, 5.34) 5.95 (3.54,9.98)
 Height (m) .035
  1.308 ≤ Tertile 1 < 1.559 3,285 2,434 (74.1) 543 (16.5) 308 (9.4) 1.0 (referent) 3.08 (2.35, 4.05) 6.69 (4.93,9.09)
  1.559 ≤ Tertile 2 < 1.611 3,294 2,826 (85.8) 324 (9.8) 144 (4.4) 1.0 (referent) 3.16 (2.23, 4.48) 5.57 (3.69,8.40)
  1.611 ≤ Tertile 3 < 1.826 3,318 3,052 (92.0) 198 (6.0) 68 (2.1) 1.0 (referent) 4.11 (2.75, 6.14) 10.24 (5.98,17.54)
 Cancer: Yes 2,087 1,773 (85.0) 229 (11.0) 85 (4.1) 1.0 (referent) 5.25 (3.47, 7.96) 10.67 (6.20,18.36) .081
 Cancer: No 7,340 6,228 (84.9) 747 (10.2) 365 (5.0) 1.0 (referent) 3.39 (2.71, 4.25) 7.08 (5.45,9.19)
 CHF: Yes 536 398 (74.3) 84 (15.7) 54 (10.1) 1.0 (referent) 4.10 (2.29, 7.34) 5.31 (2.67,10.58) .277
 CHF: No 8,365 7,158 (85.6) 807 (9.7) 400 (4.8) 1.0 (referent) 3.65 (2.96, 4.50) 8.04 (6.29,10.27)
 COPD: Yes 703 591 (84.1) 82 (11.7) 30 (4.3) 1.0 (referent) 2.21 (1.02, 4.77) 9.23 (3.74,22.82) .663
 COPD: No 7,445 6,412 (86.1) 681 (9.2) 352 (4.7) 1.0 (referent) 3.90 (3.11, 4.89) 7.44 (5.72,9.67)
 Diabetes: Yes 1,157 908 (78.5) 154 (13.3) 95 (8.2) 1.0 (referent) 2.70 (1.75, 4.17) 6.72 (4.08,11.05) .348
 Diabetes: No 8,708 7,389 (84.9) 903 (10.4) 416 (4.8) 1.0 (referent) 3.88 (3.15, 4.78) 7.54 (5.89,9.66)
Women ≥20 kg 16–19.9 kg <16 kg <16 kg 16–19.9 kg ≥20 kg
 All 10,950 6,249 (57.1) 2,736 (25.0) 1,965 (18.0) 1.0 (referent) 2.44 (2.20, 2.71) 4.42 (3.94,4.97)
 Age
  65–79 6,772 4,523 (66.8) 1,417 (20.9) 832 (12.3) 1.0 (referent) 2.27 (1.95, 2.63) 3.70 (3.11,4.40) .323
  80 4,178 1,726 (41.3) 1,319 (31.6) 1,133 (27.1) 1.0 (referent) 1.97 (1.69, 2.29) 3.49 (2.96,4.12)
 Body mass index
  Underweight 210 80 (38.1) 63 (30.0) 67 (31.9) 1.0 (referent) 2.83 (1.26, 6.35) 4.6 (2.11,10.02) .497
  Normal weight‡ 3,926 2,032 (51.8) 1,035 (26.4) 859 (21.9) 1.0 (referent) 2.45 (2.05, 2.94) 4.80 (4.01,5.75)
  Overweight 4,104 2,427 (59.1) 1,017 (24.8) 660 (16.1) 1.0 (referent) 2.71 (2.28, 3.21) 4.74 (3.89,5.77)
  Obese 2,710 1,710 (63.1) 621 (22.9) 379 (14.0) 1.0 (referent) 2.38 (1.95, 2.90) 4.41 (3.45,5.64)
 Height (m)
  1.470 ≤ Tertile 1 < 1.710 3,635 1,545 (42.5) 1,107 (30.5) 983 (27.0) 1.0 (referent) 2.08 (1.74, 2.48) 3.80 (3.15,4.58) .116
  1.710 ≤ Tertile 2 < 1.767 3,652 2,157 (59.1) 926 (25.4) 569 (15.6) 1.0 (referent) 2.46 (2.05, 2.94) 4.56 (3.69,5.64)
  1.767 ≤ Tertile 3 < 1.989 3,663 2,547 (69.5) 703 (19.2) 413 (11.3) 1.0 (referent) 2.56 (2.11, 3.10) 4.09 (3.26,5.13)
 Cancer: Yes 591 394 (66.7) 134 (22.7) 63 (10.7) 1.0 (referent) 3.16 (2.06, 4.83) 4.51 (2.52,8.06) .303
 Cancer: No 4,716 3,381 (71.7) 832 (17.6) 503 (10.7) 1.0 (referent) 2.78 (2.34, 3.30) 3.54 (2.86,4.38)
 CHF: Yes 448 204 (45.5) 132 (29.5) 112 (25.0) 1.0 (referent) 2.42 (1.50, 3.90) 4.92 (2.86,8.48) .944
 CHF: No 9,394 5,236 (55.7) 2,409 (25.6) 1,749 (18.6) 1.0 (referent) 2.52 (2.25, 2.81) 4.49 (3.97,5.08)
 COPD: Yes 649 322 (49.6) 197 (30.4) 130 (20.0) 1.0 (referent) 3.08 (2.08, 4.55) 5.49 (3.46,8.73) .221
 COPD: No‡ 8,165 4,480 (54.9) 2,142 (26.2) 1,543 (18.9) 1.0 (referent) 2.26 (2.02, 2.53) 3.92 (3.47,4.43)
 Diabetes: Yes 789 476 (60.3) 182 (23.1) 131 (16.6) 1.0 (referent) 2.81 (1.94, 4.06) 2.32 (1.53,3.51) .095
 Diabetes: No 10,003 5,691 (56.9) 2,518 (25.2) 1,794 (17.9) 1.0 (referent) 2.44 (2.19, 2.72) 4.64 (4.11,5.25)
Notes: CHF = Congestive heart failure; COPD = chronic obstructive pulmonary disease.
*Odds ratio (OR) from logistic regression predicting probability of gait speed <0.8 m/s with random effect for study.
†p for interaction between strength groups and row characteristic in predicting walking speed.
‡ORs reflect model without random effect (required for model convergence).
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Persons defined weakness based on a grip strength less than 
30 kg in men and less than 20 kg in women (9). This defini-
tion corresponds most closely to the cutpoints we identified 
to classify the intermediate level of weakness. The cutpoints 
identified here as “weak” are lower (<26 kg in men and <16 
kg in women) and resulted in a smaller proportion of the 
population being classified as weak (13).
Importantly, the role of BMI differed by gender. In mod-
els including all potential variations on grip strength and 
body size (grip strength, body size, and grip strength/body 
size ratios), grip strength alone was the best predictor for 
men, whereas grip strength/BMI was the best predictor for 
women. After carrying forward both definitions for addi-
tional analysis and comparing the strength of the relation-
ships between weakness and slowness, as well as model fit 
statistics, neither definition performed consistently better 
than the other. In the absence of clear evidence that includ-
ing BMI in the definition of weakness added to our ability 
to predict mobility disability, we elected to use the simpler 
indicator of weakness unadjusted for BMI.
Although the two different definitions of weakness had 
similar relationships with slow walking (as indicated by 
the strength of the relationship and the model fit statistics), 
they characterized different subgroups of the population 
as weak—a group with limited ability to generate strength 
and a group unable to generate sufficient strength relative to 
BMI. Because the a priori focus of this analysis was on iden-
tifying a subgroup of older adults in whom weakness might 
be due to low lean mass, we selected the definition based on 
strength unadjusted for BMI. However, another group may 
exist in whom weakness is due to low muscle quality.
It remains unclear why BMI would be more important for 
women than for men. This may be an artifact of the samples 
used in this analysis. Men and women were drawn from 
different study populations (MrOs in men, SOF in women, 
different UCONN clinical trials available for each gender). 
It may also reflect sex differences in body composition or 
the association between strength and mobility. Strength 
declines more rapidly in men at older ages (32), and the 
association between strength and physical function appears 
stronger in men than in women (5,33).
A central finding of this analysis is the lack of a clear 
threshold effect in the association between grip strength 
and gait speed. Previous research has reported nonlin-
earities in the relationship between strength and mobility 
(1,3), suggesting that there may a level of strength below 
which mobility becomes more difficult. However, we did 
not find evidence of a threshold in the relationship between 
grip strength and gait speed. Although grip strength is well 
correlated with lower extremity strength and is associated 
with mobility outcomes, it may not detect subtle differ-
ences in the association between lower extremity strength 
and function. However, preliminary analysis of knee exten-
sion strength also did not demonstrate nonlinearities in the 
association of strength and gait speed. It is possible that 
other measures of function, such ability to rise from a chair, 
would exhibit threshold effects that we were not able to 
observe using gait speed as an outcome. However, we were 
unable to examine inability to rise from a chair as a mobil-
ity outcome, because of low prevalence in this sample. 
The populations included in the FNIH Sarcopenia Project 
were all drawn from community-dwelling samples of older 
adults and may be underrepresentative of older populations 
with mobility limitations and weakness. Notably, however, 
some other studies have also been unable to identify thresh-
olds in the association between strength and functional per-
formance (34). Importantly, strength is one of many factors 
that influence gait speed, including balance, vision, cogni-
tion, and muscle power.
We used CART to identify weakness cutpoints, but it is 
important to recognize limitations in this approach. First, 
CART, by definition, partitions data into groups, even when 
the underlying relationship between the predictor and out-
come is linear. Second, our CART models did not account 
for differences between studies included in the model, 
although we accounted for study in subsequent logistic 
models. Finally, no statistical model alone can identify a 
disease state, thus further work is necessary to understand 
the physiological implications of these results.
The definition of weakness proposed here relies on grip 
strength measurement. Although grip strength was meas-
ured using a variety of protocols, the proposed strength cut-
points performed well across cohorts. Unfortunately, data 
are unavailable from the present studies to directly com-
pare measurement across protocols. By using the maximum 
measured grip strength from either hand, we sought to mini-
mize variation based on these factors, but variation due to 
dynamometer used, hand position, and other factors may 
still exist (28). Future research should consider standard-
ized protocols to facilitate comparison (28).
The analysis used a data-driven approach in a large and 
diverse pooled data set to identify weakness cutpoints asso-
ciated with mobility impairment defined by gait speed. This 
is an important first step in identifying populations that may 
benefit from interventions to improve strength and muscle 
function. Results from this analysis highlight the utility of 
an absolute measure of weakness across population groups 
but also point to the need to consider strength relative to 
body size, particularly in women. Results also cast doubt on 
the existence of a strong threshold effect in the association 
between strength and gait speed, suggesting that increases 
in strength may have positive effects on physical function 
across the spectrum of strength observed in community-
dwelling older adults. Despite lack of strong evidence of 
threshold effects, criteria for the identification of weakness 
may help identify populations that would experience the 
greatest benefit from interventions to improve strength and 




Supplementary material can be found at: http://biomedgerontology.
oxfordjournals.org/
Funding
Funding support for the conference and the work of the consortium 
was provided by the National Institute on Aging (1U13AG041583 and 
P30 AG024827), the Food and Drug Administration, and through grants 
from the Foundation for the NIH, made possible by funding from Abbott 
Nutrition, Amgen, Eli Lilly, Merck, Novartis, and The Dairy Research 
Institute. This research was supported in part by the Intramural Research 
Program of the NIH, National Institute on Aging. Additional acknowledge-
ments for each contributing cohort and members of the FNIH Sarcopenia 
Project can be found in an online supplement.
References
 1. Ferrucci L, Guralnik JM, Buchner D, et al. Departures from linearity 
in the relationship between measures of muscular strength and physi-
cal performance of the lower extremities: the Women’s Health and 
Aging Study. J Gerontol A Biol Sci Med Sci. 1997;52:M275–M285.
 2. Manini TM, Clark BC. Dynapenia and aging: an update. J Gerontol 
A Biol Sci Med Sci. 2012;67:28–40.
 3. Manini TM, Visser M, Won-Park S, et al. Knee extension strength cut-
points for maintaining mobility. J Am Geriatr Soc. 2007;55:451–457.
 4. Sallinen J, Stenholm S, Rantanen T, Heliövaara M, Sainio P, Koskinen 
S. Hand-grip strength cutpoints to screen older persons at risk for 
mobility limitation. J Am Geriatr Soc. 2010;58:1721–1726.
 5. Hicks GE, Shardell M, Alley DE, et  al. Absolute strength and loss 
of strength as predictors of mobility decline in older adults: the 
InCHIANTI study. J Gerontol A Biol Sci Med Sci. 2012;67:66–73.
 6. Lauretani F, Russo CR, Bandinelli S, et al. Age-associated changes in 
skeletal muscles and their effect on mobility: an operational diagnosis 
of sarcopenia. J Appl Physiol (1985). 2003;95:1851–1860.
 7. Bandeen-Roche K, Xue QL, Ferrucci L, et al. Phenotype of frailty: 
characterization in the women’s health and aging studies. J Gerontol 
A Biol Sci Med Sci. 2006;61:262–266.
 8. Fielding RA, Vellas B, Evans WJ, et al. Sarcopenia: an undiagnosed 
condition in older adults. Current consensus definition: prevalence, 
etiology, and consequences. International working group on sarcope-
nia. J Am Med Dir Assoc. 2011;12:249–256.
 9. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et  al.; European Working 
Group on Sarcopenia in Older People. Sarcopenia: European con-
sensus on definition and diagnosis: report of the European Working 
Group on Sarcopenia in Older People. Age Ageing. 2010;39:412–423.
 10. Studenski SA, Peters KW, Alley DE, et al. The FNIH sarcopenia pro-
ject: rationale and study description. J Gerontol A Biol Sci Med Sci. 
2014;5:547–558.
 11. Cawthon PM, Peters KW, Shardell MD, et al. Cut-points for low 
appendicular lean mass that identify older adults with clinically sig-
nificant weakness. J Gerontol A Biol Sci Med Sci. 2014;5:567–575.
 12. McLean RR, Peters KW, Shardell MD, et al. Criteria for clinically 
relevant weakness and low lean mass and their longitudinal associa-
tion with incident mobility impairment and mortality: the Foundation 
for the National Institutes of Health (FNIH) Sarcopenia Project. 
J Gerontol A Biol Sci Med Sci. 2014;5:576–583.
 13. Dam TL, Peters KW, Fragala M, et al. An evidence-based comparison 
of candidate criteria for the presence of sarcopenia. J Gerontol A Biol 
Sci Med Sci. 2014;5:584–590.
 14. Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip 
fracture in white women. Study of Osteoporotic Fractures Research 
Group. N Engl J Med. 1995;332:767–773.
 15. Cauley JA, Lui LY, Ensrud KE, et al. Bone mineral density and the 
risk of incident nonspinal fractures in black and white women. JAMA. 
2005;293:2102–2108.
 16. Orwoll E, Blank JB, Barrett-Connor E, et  al. Design and baseline 
characteristics of the osteoporotic fractures in men (MrOS) study–a 
large observational study of the determinants of fracture in older men. 
Contemp Clin trials. 2005;26:569–585.
 17. Newman AB, Haggerty CL, Goodpaster B, et al.; Health Aging And 
Body Composition Research Group. Strength and muscle quality in a 
well-functioning cohort of older adults: the Health, Aging and Body 
Composition Study. J Am Geriatr Soc. 2003;51:323–330.
 18. Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An 
investigation of coronary heart disease in families. The Framingham 
offspring study. Am J Epidemiol. 1979;110:281–290.
 19. Dawber TR, Meadors GF, Moore FE Jr. Epidemiological approaches 
to heart disease: the Framingham Study. Am J Public health Nations 
health. 1951;41:279–281.
 20. Ferrucci L, Bandinelli S, Benvenuti E, et al. Subsystems contributing 
to the decline in ability to walk: bridging the gap between epidemiol-
ogy and geriatric practice in the InCHIANTI study. J Am Geriatr Soc. 
2000;48:1618–1625.
 21. Tucker KL, Mattei J, Noel SE, et al. The Boston Puerto Rican Health 
Study, a longitudinal cohort study on health disparities in Puerto 
Rican adults: challenges and opportunities. BMC Public health. 
2010;10:107.
 22. Harris TB, Launer LJ, Eiriksdottir G, et al. Age, Gene/Environment 
Susceptibility-Reykjavik Study: multidisciplinary applied phenomics. 
Am J Epidemiol. 2007;165:1076–1087.
 23. Hutchins-Wiese HL, Kleppinger A, Annis K, et al. The impact of sup-
plemental n-3 long chain polyunsaturated fatty acids and dietary anti-
oxidants on physical performance in postmenopausal women. J Nutr 
health Aging. 2013;17:76–80.
 24. Kenny AM, Boxer RS, Kleppinger A, Brindisi J, Feinn R, Burleson 
JA. Dehydroepiandrosterone combined with exercise improves mus-
cle strength and physical function in frail older women. J Am Geriatr 
Soc. 2010;58:1707–1714.
 25. Prestwood KM, Kenny AM, Kleppinger A, Kulldorff M. Ultralow-
dose micronized 17beta-estradiol and bone density and bone 
metabolism in older women: a randomized controlled trial. JAMA. 
2003;290:1042–1048.
 26. Judge JO, Kleppinger A, Kenny A, Smith JA, Biskup B, Marcella G. 
Home-based resistance training improves femoral bone mineral density 
in women on hormone therapy. Osteoporos Int. 2005;16:1096–1108.
 27. Giampaoli S, Ferrucci L, Cecchi F, et  al. Hand-grip strength pre-
dicts incident disability in non-disabled older men. Age Ageing. 
1999;28:283–288.
 28. Roberts HC, Denison HJ, Martin HJ, et al. A review of the measure-
ment of grip strength in clinical and epidemiological studies: towards 
a standardised approach. Age Ageing. 2011;40:423–429.
 29. Breiman L, Friedman J, Stone CJ, Olshen RA. Classification and 
Regression trees. Belmont, CA: Wadsworth International Group; 1984.
 30. Tilson JK, Sullivan KJ, Cen SY, et al.; Locomotor Experience Applied 
Post Stroke (LEAPS) Investigative Team. Meaningful gait speed 
improvement during the first 60 days poststroke: minimal clinically 
important difference. Phys ther. 2010;90:196–208.
 31. Maindonald J, Braun WJ. Data Analysis and Graphics Using R: An 
Example-Based Approach. 3rd ed. Cambridge: Cambridge University 
Press; 2010.
 32. Goodpaster BH, Park SW, Harris TB, et al. The loss of skeletal muscle 
strength, mass, and quality in older adults: the Health, Aging and Body 
Composition Study. J Gerontol A Biol Sci Med Sci. 2006;61:1059–1064.
 33. Visser M, Deeg DJ, Lips P, Harris TB, Bouter LM. Skeletal muscle 
mass and muscle strength in relation to lower-extremity performance 
in older men and women. J Am Geriatr Soc. 2000;48:381–386.
 34. Marsh AP, Miller ME, Saikin AM, et al. Lower extremity strength and 
power are associated with 400-meter walk time in older adults: the 
InCHIANTI study. J Gerontol A Biol Sci Med Sci. 2006;61:1186–1193.
